Life Biosciences subsidiary RenGene Bio unveiled China's first fully human nanobody rat (HuNano Rat) platform on 23 July, overcoming industry bottlenecks in nanobody development. The platform uses megabase-scale gene editing to enable rats to produce diverse, high-affinity human single-chain antibodies, offering 10-fold higher throughput than traditional camelid sources while reducing antigen requirements and avoiding humanisation steps.

The technology addresses challenges in radiopharmaceuticals (RDC), CAR-T therapies and neurological drugs by providing smaller, more stable binding domains. Life also operates a complementary nanobody mouse platform, allowing dual-species comparative studies. The platform's applications span difficult targets like blood-brain barrier-penetrating neurotherapeutics.

According to PharmCube's NextBiopharm® database, over 300 nanobody drugs are under active development globally, most of which are oncology therapies. Click here to request a free trial for NextBiopharm®.